Anticancer vaccines based on Hsp70–peptide complexes, obtained from autologous tumor lysates, have been introduced into clinical trials of various cancers, including melanoma, glioblastoma, renal, gastric or pancreatic carcinoma, and, although in a significant number of patients the immune responses were induced, only in certain subgroups was this effect clinically relevant [263]. This evidence concerns the gene HSPA4 and cancer.